ERBB2 and breast carcinoma: Surprisingly, De Cola et al. found that miR-205 was upregulated in HER2-positive patients derived-breast cancer stem cells, and its increased levels promoted targeted therapy resistance via downregulating ERBB2 and EGFR in a p63-dependent manner [24].